


Claims

1. The compounds of general formula (1)



5 in which:

- (a) represents a single bond or a double bond;
- W represents a CH, CH<sub>2</sub>, CHCH<sub>3</sub>, CCH<sub>3</sub> or C(CH<sub>3</sub>)<sub>2</sub> group, a C(CH<sub>2</sub>)<sub>2</sub> group (i.e. a carbon atom bearing two methylene groups linked together so as to form a spiro-cyclopropane unit) or a C(CH<sub>2</sub>)<sub>3</sub> group (i.e. a carbon atom bearing two methylene groups linked to another methylene group so as to form a spiro-cyclobutane unit) with the proviso, however, that when (a) is a double bond, then W exclusively represents a CH or CCH<sub>3</sub> group, and that when (a) is a single bond, then W exclusively represents a CH<sub>2</sub>, CHCH<sub>3</sub>, C(CH<sub>3</sub>)<sub>2</sub>, C(CH<sub>2</sub>)<sub>2</sub> or C(CH<sub>2</sub>)<sub>3</sub> group;
- X is a carbon atom bearing a hydrogen atom (CH) or a nitrogen atom;
- Y is a hydrogen atom or a fluorine atom;


their addition salts and optionally the hydrates of the addition salts with pharmaceutically acceptable inorganic acids or organic acids and their tautomeric forms, the pure enantiomers and mixtures of racemic or nonracemic enantiomers.

2. The derivatives as claimed in claim 1, characterized in that they are chosen from the following compounds:

- 30 [2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;
- [2-(benzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)-amine;
- [2-(2-methylbenzofuran-7-yloxy)ethyl]-(3-cyclopenten-

1-ylbenzyl)amine;  
[2-(2,3-dihydrobenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;  
[2-(2-spirocyclopropyl-2,3-dihydrobenzofuran-7-yloxy)-  
5 ethyl]-(3-cyclopenten-1-ylbenzyl)amine;  
[2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-  
[3-(2-fluorocyclopenten-1-yl)benzyl]amine;  
[2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-  
10 (5-cyclopenten-1-ylpyridine-3-ylmethyl)amine;  
their addition salts and optionally the hydrates of  
addition salts with pharmaceutically acceptable inorganic  
acids or organic acids and their isomers and their  
tautomers.

15 3. A compound of formula (2):



in which **X** and **Y** have the same meaning as in formula (1)  
as synthesis intermediate involved in the preparation of  
the compounds of formula (1).

20 4. A compound as claimed as claimed in either of claims  
1 and 2, as medicaments.

25 5. A pharmaceutical composition, characterized in that  
it contains, as active ingredient, at least one compound  
as claimed in either of claims 1 and 2 combined with an  
inert pharmaceutical carrier or other pharmaceutically  
acceptable vehicles and optionally with another  
medicament.

30 6. The pharmaceutical composition as claimed in  
claim 5, which is useful in the treatment of  
schizophrenia or useful in the treatment of the  
progression of schizophrenia.